Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRB2104
- Development stage
- Preclinical
- Lead developer
- Biocytogen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
CRB2104 is a preclinical-stage, bispecific T-cell engager (TCE) designed with a 2:1 format featuring bivalent high-affinity arms targeting anti-Müllerian hormone receptor type 2 (AMHR2) and an affinity-optimized CD3-binding arm. Developed by Biocytogen and China Resources Angde Biopharmaceutical, CRB2104 is designed to treat AMHR2-positive solid tumors, such as epithelial ovarian cancer and colorectal cancer, by inducing potent tumor-specific T-cell-mediated cytotoxicity while minimizing the risk of cytokine release syndrome (CRS).
02
Targets
CD3 (T-cell surface glycoprotein CD3)FCGRT (Neonatal crystallizable fragment receptor)AMHR2 (Anti-Müllerian hormone receptor type 2)
Beyond the preview
Go deeper on CRB2104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRB2104.